Pyripyropene A
Based on 1 publication(s) in Google Scholar
Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.37%
- CAS No.: 147444-03-9
- Formule: C31H37NO10
- Masse moléculaire:583.63
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-13215
AvasimibeACAT/SOAT Inhibitor -
HY-100400A
K-604 dihydrochlorideACAT1 Inhibitor -
HY-100401A
Pactimibe sulfateACAT1/2 Inhibitor -
HY-119738
OSMI-1O-GlcNAc Transferase Inhibitor -
HY-N6719
Fumonisin B1Sphingosine N-acyltransferase Inhibitor -
HY-135425
10,12-Tricosadiynoic acidACOX1 Inhibitor -
HY-114361
OSMI-4OGT Inhibitor -
HY-100401
PactimibeACAT1/2 Inhibitor -
HY-136282
ST045849OGT Inhibitor -
HY-112825
TSI-01LPCAT2 Inhibitor -
HY-13215R
Avasimibe (Standard)ACAT/SOAT Inhibitor -
HY-N6723
Fumonisin B2Ceramide Synthase Inhibitor
Publications Citing Use of MedChemExpress (MCE) Pyripyropene A
More
Activité biologique
Description
IC50 & Target
IC50: 0.07 µM (ACAT2)[1]
In Vitro
Pyripyropene A (0-100 μM; 72 hours) exhibits anti-proliferative activity against HUVECs, and with an IC50 value of 1.8 μM[1].
?
Pyripyropene A (10 μM ; 24 hours) inhibits VEGF (20 ng/ml)-induced migration and tubular formation of HUVECs in dose-dependent fashion[1].
?
Pyripyropene A do not show growth inhibitory effects against KB3-1, K562 and Neuro2A cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVECs
-
Concentration:0-100 µM
-
Incubation Time:72 hours
-
Result:Exhibited anti-proliferative activity against HUVECs with an IC50 value of 1.8 µM.
In Vivo
? Pyripyropene A inhibits the hepatic e acyl–coenzyme A:cholesterol acyltransferase 2? (ACAT2) activity in vivo[3].
? Pyripyropene A displays a half-life (t1/2) of 0.693/λ, where λ represented the terminal slope of the log-linear portion of concentration time profile[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice[2]
-
Dosage:0 mg/kg, 1 mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg
-
Administration:Oral administration; daily; for 12 weeks
-
Result:Reduced atherogenic lesion areas in the aortae and heart.
-
Animal Model:9-week old male ICR mice (pharmacokinetic analysis)[4]
-
Dosage:5 mg/kg ,10 mg/kg
-
Administration:Oral administration
-
Result:t1/2 = 0.693/λ
Chemical Information
-
CAS No. 147444-03-9
-
Appearance Solid
-
Masse moléculaire 583.63
-
Formule C31H37NO10
-
Color White to light yellow
-
SMILES
O=C1OC(C2=CC=CN=C2)=CC3=C1[C@H](O)[C@@]4([H])[C@]([C@@H](OC(C)=O)C[C@@]5([H])[C@](C)(COC(C)=O)[C@@H](OC(C)=O)CC[C@@]54C)(C)O3
-
Structure Classification
-
Initial Source
filamentous fungi
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Transcription factor ETV4 plays a critical role in the development of non-alcoholic fatty liver disease. [Abstract]2024 Dec;282(Pt 5):137235. PMID: 39500423
Solvant et solubilité
In Vitro:
Methanol : 10 mg/mL (17.13 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hayashi A, et al. Pyripyropenes, fungal sesquiterpenes conjugated with alpha-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells. Biol Pharm Bull. 2009 Jul;32(7):1261-5. [Content Brief]
[2]. Ohtawa M, et al. Design and Synthesis of A-Ring Simplified Pyripyropene A Analogues as Potent and Selective Synthetic SOAT2 Inhibitors. ChemMedChem. 2018 Mar 6;13(5):411-421. [Content Brief]
[3]. Ohshiro T, et al. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1108-15. [Content Brief]
[4]. Lee KR , et al. Determination of Penicillium griseofulvum-oriented pyripyropene A, a selective inhibitor of acyl-coenzyme A:cholesterol acyltransferase 2, in mouse plasma using liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. Biomed Chromatogr. 2019 Feb;33(2):e4388. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Methanol | 1 mM | 1.7134 mL | 8.5671 mL | 17.1341 mL | 42.8354 mL |
| 5 mM | 0.3427 mL | 1.7134 mL | 3.4268 mL | 8.5671 mL | |
| 10 mM | 0.1713 mL | 0.8567 mL | 1.7134 mL | 4.2835 mL | |
| 15 mM | 0.1142 mL | 0.5711 mL | 1.1423 mL | 2.8557 mL |
Pyripyropene A Related Classifications
HY-117832 Related Classifications
Powered by Bioz